FDA rejects Disc Medicine drug for rare genetic disorder
The FDA declined to approve a Disc Medicine drug for a rare genetic disorder. The company announced the regulatory decision on Friday after a federal review.
Insights:
The U.S. Food and Drug Administration declined to approve a drug from Disc Medicine, Inc. on Feb. 13, 2026. The therapy is intended to treat a rare genetic disorder and will not receive U.S. approval following this regulatory determination. The decision by the agency is now completed and represents a significant development for the company's pipeline in the US 
US.
US.This action by the U.S. Food and Drug Administration prevents U.S. approval of the therapy and directly changes the drug's regulatory status in the United States. By declining the application, the regulator has altered the legal standing of the treatment, which was specifically developed to treat a rare genetic disorder.
